Antibody oligonucleotide conjugates as an RNA strategy with the CEO of Avidity Biosciences
Sarah Boyce explains the rationale for using AOCs against muscle disorders like myotonic dystrophy type 1 and DMD, and describes the clinical data Avidity has collected so far.
Comments